Table 1 Characteristics of the studies included.
Study | Acronym and protocol registration number | Treatment allocation | No of patients | Age in years (median and range) and gender distribution (female%) | Follow-up period (median, in months) | |
|---|---|---|---|---|---|---|
Daratumumab | Control | |||||
Studies reporting on newly diagnosed multiple myeloma regardless of cytogenetic risk | ||||||
Facon et al.22 | MAIA (NCT02252172) | DRd vs Rd | 737 | 73 [50–90] (n.r.) | 74 [45–89] (n.r.) | 28.0 |
Moreau et al.27 | CASSIOPEIA (NCT02541383) | DVTd vs VTd | 1085 | 59 [22–65] (42%) | 58 [26–65] (41%) | 18.8 |
Mateos et al.25 | ALCYONE (NCT02195479) | DVMP vs VMP | 706 | 71 [40–93] (54%) | 71 [50–91] (53%) | 40.1 |
Voorhees et al.29 | GRIFFIN (NCT02874742) | DRVd vs RVd | 207 | 59 [29–70] (44%) | 61 [40–70] (42%) | 13.5 |
Studies reporting on cytogenetic subgroups in newly diagnosed multiple myeloma | ||||||
Mateos et al.26 | ALCYONE (NCT02195479) | DVMP v. VMP | 706 | 71 [40–93] (54%) | 71 [50–91] (53%) | 16.5 |
Facon et al.22 | MAIA (NCT02252172) | DRd vs Rd | 737 | 73 [50–90] (n.r.) | 74 [45–89] (n.r.) | 28.0 |
Moreau et al.27 | CASSIOPEIA (NCT02541383) | DVTd vs VTd | 1085 | 59 [22–65] (42%) | 58 [26–65] (41%) | 18.8 |
Studies reporting on relapsed/refractory multiple myeloma regardless of cytogenetic risk | ||||||
Dimopoulos et al.20 | POLLUX (NCT02076009) | DRd vs Rd | 569 | 73 [50–90] (n.r.) | 74 [45–89] (n.r.) | 13.5 |
Palumbo et al.28 | CASTOR (NCT02136134) | DVd vs Vd | 498 | 64 [30–88] (45%) | 44 [33–85] (41%) | 7.4 |
Dimopoulos et al.19 | CANDOR (NCT03158688) | KdD vs Kd | 466 | 64 [57–70]* (43%) | 64.5 [59–71]* (41%) | 17.2 |
Dimopoulos et al.21 | APOLLO (NCT03180736) | DPd vs Pd | 304 | 67 [42–86] (48%) | 68 [35–90] (46%) | 16.9 |
Lu et al.24 | LEPUS (NCT03234972) | DVd vs Vd | 211 | 61 [28–79] (40%) | 61 [43–82] (40%) | 8.2 |
Studies reporting on cytogenetic subgroups in relapsed/refractory multiple myeloma | ||||||
Dimopoulos et al.19 | CANDOR (NCT03158688) | KdD vs Kd | 466 | 64 [57–70]* (43%) | 64.5 [59–71]* (41%) | 17.2 |
Kaufman et al.23 | POLLUX (NCT02076009) | DRd vs Rd | 569 | 73 [50–90] (n.r.) | 74 [45–89] (n.r.) | 44.3 |
Weisel et al.30 | CASTOR (NCT02136134) | DVd vs Vd | 498 | 64 [30–88] (45%) | 44 [33–85] (41%) | 40.0 |
Dimopoulos et al.21 | APOLLO (NCT03180736) | DPd vs Pd | 304 | 67 [42–86] (48%) | 68 [35–90] (46%) | 16.9 |
Lu et al.24 | LEPUS (NCT03234972) | DVd vs Vd | 211 | 61 [28–79] (40%) | 61 [43–82] (40%) | 8.2 |
